Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 21, 2021 - Issue 1
Submit an article Journal homepage
325
Views
6
CrossRef citations to date
0
Altmetric
Original Research

The current state of patient access to new drugs in South Korea under the positive list system: evaluation of the changes since the new review pathways

Sungju Kima Healthcare Group, Lee&Ko, Seoul, Republic of KoreaView further author information
,
Hyunyoung Chob Department of Market Access, AbbVie Korea, Seoul, Republic of KoreaView further author information
,
Jinhong Kimc Department of Market Access, GlaxoSmithKline Korea, Seoul, Republic of KoreaView further author information
,
Kyungmin Leed Department of Patient Access and Public Affairs, Novartis Korea, Seoul, Republic of KoreaView further author information
&
Jong Hyuk Leee Department of Pharmaceutical Engineering, College of Life and Health Sciences, Hoseo University, Asan, Republic of KoreaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-9932-8879View further author information
ORCID Icon
Pages 119-126 | Received 20 Mar 2020, Accepted 17 Apr 2020, Published online: 26 Apr 2020

Citations (6)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Jong Hyuk Lee & Seung-Lai Yoo. (2022) Pricing and reimbursement policy for new orphan drugs in South Korea: focused on patient accessibility and budget impact. Expert Opinion on Orphan Drugs 10:1, pages 22-27.
Read now
Sungju Kim, Jinhong Kim, Hyunyoung Cho, Kyungmin Lee, Chiyoung Ryu & Jong Hyuk Lee. (2021) Trends in the pricing and reimbursement of new anticancer drugs in South Korea: an analysis of listed anticancer drugs during the past three years. Expert Review of Pharmacoeconomics & Outcomes Research 21:3, pages 479-488.
Read now

Articles from other publishers (4)

Sungju Kim, Ji Yeon Lee, Seong Ha Cho, Eileen J. Shin, Minyoung Kim & Jong Hyuk Lee. (2023) An Industry Survey on Unmet Needs in South Korea’s New Drug Listing System. Therapeutic Innovation & Regulatory Science 57:4, pages 759-768.
Crossref
SungKyung Lee & Jong Hyuk Lee. (2023) Cell and gene therapy regulatory, pricing, and reimbursement framework: With a focus on South Korea and the EU. Frontiers in Public Health 11.
Crossref
Jong Hyuk Lee. (2021) Pricing and Reimbursement Pathways of New Orphan Drugs in South Korea: A Longitudinal Comparison. Healthcare 9:3, pages 296.
Crossref
Sungju Kim & Jong Hyuk Lee. (2020) Price-Cutting Trends in New Drugs after Listing in South Korea: The Effect of the Reimbursement Review Pathway on Price Reduction. Healthcare 8:3, pages 233.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.